US Department of Defense Begins Clinical Trial

At PharmaLive, they divulge information on the new post traumatic stress disorder clinical trail the DoD will be doing for war vets returning from Operation Iraqi Freedom and Operation Enduring Freedom. This Phase II multisite clinical trial will be lead by the three leading researchers in the PTSD field: Lori L. Davis, M.D, Tom Kosten, M.D, and Mark Hamner, M.D. The first six week trial is a prospective, randomized, double-blind, placebo-controlled study of nepicastat, a dopamine ? hydroxylase (DBH) inhibitor. An eight week extension phase will follow this.

According to the article, the goal will be:

The primary aim of the study is to assess the efficacy and tolerability of nepicastat in the treatment of PTSD-induced hyperarousal, with the secondary aims of assessing its ability to improve other symptoms of PTSD, induce remission and improve quality of life.

The first patients will enroll in the study this September.